JP2021524256A5 - - Google Patents
Info
- Publication number
- JP2021524256A5 JP2021524256A5 JP2020565492A JP2020565492A JP2021524256A5 JP 2021524256 A5 JP2021524256 A5 JP 2021524256A5 JP 2020565492 A JP2020565492 A JP 2020565492A JP 2020565492 A JP2020565492 A JP 2020565492A JP 2021524256 A5 JP2021524256 A5 JP 2021524256A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- variable region
- chain variable
- antibody
- antigen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024022697A JP2024056938A (ja) | 2018-05-23 | 2024-02-19 | 抗ｏｘ４０抗体及び使用方法 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2018088101 | 2018-05-23 | ||
| CNPCT/CN2018/088101 | 2018-05-23 | ||
| PCT/CN2019/088013 WO2019223733A1 (en) | 2018-05-23 | 2019-05-22 | Anti-ox40 antibodies and methods of use |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024022697A Division JP2024056938A (ja) | 2018-05-23 | 2024-02-19 | 抗ｏｘ４０抗体及び使用方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021524256A JP2021524256A (ja) | 2021-09-13 |
| JP2021524256A5 true JP2021524256A5 (https=) | 2022-05-23 |
| JP7489922B2 JP7489922B2 (ja) | 2024-05-24 |
Family
ID=68615676
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020565492A Active JP7489922B2 (ja) | 2018-05-23 | 2019-05-22 | 抗ｏｘ４０抗体及び使用方法 |
| JP2024022697A Withdrawn JP2024056938A (ja) | 2018-05-23 | 2024-02-19 | 抗ｏｘ４０抗体及び使用方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024022697A Withdrawn JP2024056938A (ja) | 2018-05-23 | 2024-02-19 | 抗ｏｘ４０抗体及び使用方法 |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US12103974B2 (https=) |
| EP (1) | EP3797123A4 (https=) |
| JP (2) | JP7489922B2 (https=) |
| KR (1) | KR20210013708A (https=) |
| CN (1) | CN112566935B (https=) |
| AU (1) | AU2019272384A1 (https=) |
| BR (1) | BR112020023746A2 (https=) |
| EA (1) | EA202092460A1 (https=) |
| IL (1) | IL278772A (https=) |
| MX (2) | MX2020012567A (https=) |
| SG (1) | SG11202011024WA (https=) |
| TW (1) | TW202016133A (https=) |
| WO (1) | WO2019223733A1 (https=) |
| ZA (1) | ZA202006931B (https=) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112020023746A2 (pt) * | 2018-05-23 | 2021-02-17 | Beigene, Ltd. | anticorpo, composição farmacêutica, método para tratar câncer, ácido nucleico isolado, vetor, célula hospedeira, processo para a produção de um anticorpo e reagente de diagnóstico |
| US20230002500A1 (en) * | 2019-11-21 | 2023-01-05 | Beigene, Ltd. | Methods of cancer treatment using anti-ox40 antibodies in combination with anti-tigit antibodies |
| JP2023503399A (ja) * | 2019-11-21 | 2023-01-30 | ベイジーン リミテッド | 抗ｔｉｍ３抗体と組み合わせて抗ｏｘ４０抗体を用いるがんを治療する方法 |
| EP4061421A4 (en) * | 2019-11-21 | 2024-05-15 | BeiGene, Ltd. | Treatment of cancer with anti-ox40 antibodies and multi-kinase inhibitors |
| US20230011916A1 (en) * | 2019-11-21 | 2023-01-12 | Beigene, Ltd. | Methods of cancer treatment using anti-ox40 antibodies in combination with pi3 kinase delta inhibitors |
| BR112022009147A2 (pt) * | 2019-11-21 | 2022-07-26 | Beigene Ltd | Métodos de tratamento do câncer e métodos para aumentar, potencializar ou estimular uma resposta ou função imune |
| JP2023503031A (ja) * | 2019-11-21 | 2023-01-26 | ベイジーン（ベイジン）カンパニー リミテッド | 化学療法剤との組合せでの抗ｏｘ４０抗体による癌治療の方法 |
| PE20230255A1 (es) | 2020-04-17 | 2023-02-07 | Hutchison Medipharma Ltd | Anticuerpo anti-ox40 y usos del mismo |
| CN115260312B (zh) * | 2021-04-30 | 2025-02-14 | 保诺科技（北京）有限公司 | 结合ox40的抗体或抗原结合片段 |
| KR20240122784A (ko) | 2021-12-17 | 2024-08-13 | 상하이 헨리우스 바이오테크, 인크. | 항-ox40 항체 및 사용 방법 |
| KR20240116755A (ko) | 2021-12-17 | 2024-07-30 | 상하이 헨리우스 바이오테크, 인크. | 항-ox40 항체, 다중 특이적 항체 및 이의 사용 방법 |
| WO2023152116A1 (en) | 2022-02-08 | 2023-08-17 | Hookipa Biotech Gmbh | Combination therapy with arenavirus particles and immune checkpoint modulators or cytokines |
| CN120476146A (zh) * | 2022-12-30 | 2025-08-12 | 甘李药业股份有限公司 | 抗ox40抗体及其应用 |
| WO2024184810A1 (en) | 2023-03-06 | 2024-09-12 | Beigene Switzerland Gmbh | Anti-cldn6 and anti-cd3 multispecific antibodies and methods of use |
| WO2024184812A1 (en) | 2023-03-06 | 2024-09-12 | Beigene Switzerland Gmbh | Anti-cldn6 antibodies and methods of use |
| TW202436345A (zh) | 2023-03-06 | 2024-09-16 | 瑞士商百濟神州瑞士有限責任公司 | 抗ｃｄ３多特異性抗體及使用方法 |
| TW202509071A (zh) | 2023-05-12 | 2025-03-01 | 丹麥商珍美寶股份有限公司 | 能夠與ｏｘ４０結合之抗體、其變異體及其用途 |
| WO2024240247A1 (en) * | 2023-05-25 | 2024-11-28 | Beigene, Ltd. | Methods of cancer treatment using anti-ox40 antibodies in combination with anti-pd1 antibodies |
| TW202540189A (zh) | 2023-11-30 | 2025-10-16 | 德商生物新技術公司 | 在組合療法中能夠結合ｏｘ４０之抗體 |
Family Cites Families (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP3101690B2 (ja) | 1987-03-18 | 2000-10-23 | エス・ビィ・２・インコーポレイテッド | 変性抗体の、または変性抗体に関する改良 |
| AU691811B2 (en) | 1993-06-16 | 1998-05-28 | Celltech Therapeutics Limited | Antibodies |
| US6194551B1 (en) | 1998-04-02 | 2001-02-27 | Genentech, Inc. | Polypeptide variants |
| PL209392B1 (pl) | 1999-01-15 | 2011-08-31 | Genentech Inc | Przeciwciało, komórka gospodarza, sposób wytwarzania przeciwciała oraz zastosowanie przeciwciała |
| EP2097447A4 (en) | 2006-11-15 | 2010-12-29 | Medarex Inc | HUMAN MONOCLONAL ANTIBODIES AGAINST BTLA AND METHODS OF USE |
| PL2183254T3 (pl) | 2007-08-29 | 2017-10-31 | Methylgene Inc | Inhibitory aktywności białkowej kinazy tyrozynowej |
| SG10202112838YA (en) | 2008-04-09 | 2021-12-30 | Genentech Inc | Novel compositions and methods for the treatment of immune related diseases |
| HUE036157T2 (hu) * | 2010-03-30 | 2018-06-28 | Janssen Biotech Inc | Humanizált IL-25 ellenanyagok |
| AR080698A1 (es) * | 2010-04-01 | 2012-05-02 | Imclone Llc | Anticuerpo o fragmento del mismo que especificamente enlaza la variante de csf -1r humano, composicion farmaceutica que lo comprende, su uso para la manufactura de un medicamento util para el tratamiento de cancer y metodo para determinar si un sujeto es candidato para tratamiento de cancer basado e |
| CA2809089C (en) * | 2010-08-23 | 2018-12-18 | Board Of Regents, The University Of Texas System | Anti-ox40 antibodies and methods of using the same |
| CN102010407A (zh) | 2010-11-16 | 2011-04-13 | 上海科胜药物研发有限公司 | 一种合成达沙替尼的新方法 |
| GB201116092D0 (en) | 2011-09-16 | 2011-11-02 | Bioceros B V | Antibodies and uses thereof |
| HK1203971A1 (en) | 2012-05-15 | 2015-11-06 | Bristol-Myers Squibb Company | Cancer immunotherapy by disrupting pd-1/pd-l1 signaling |
| SG10201708048XA (en) | 2013-03-18 | 2017-10-30 | Biocerox Prod Bv | Humanized anti-cd134 (ox40) antibodies and uses thereof |
| CN112552401B (zh) | 2013-09-13 | 2023-08-25 | 广州百济神州生物制药有限公司 | 抗pd1抗体及其作为治疗剂与诊断剂的用途 |
| HUE045065T2 (hu) | 2014-01-31 | 2019-12-30 | Novartis Ag | TIM-3 antitest molekulák és felhasználásaik |
| SG11201607969XA (en) | 2014-03-31 | 2016-10-28 | Genentech Inc | Anti-ox40 antibodies and methods of use |
| KR20160146747A (ko) | 2014-03-31 | 2016-12-21 | 제넨테크, 인크. | 항혈관신생제 및 ox40 결합 효능제를 포함하는 조합 요법 |
| CN106604742B (zh) | 2014-07-03 | 2019-01-11 | 百济神州有限公司 | 抗pd-l1抗体及其作为治疗剂及诊断剂的用途 |
| KR20170066546A (ko) | 2014-10-03 | 2017-06-14 | 노파르티스 아게 | 조합 요법 |
| TW201619200A (zh) | 2014-10-10 | 2016-06-01 | 麥迪紐有限責任公司 | 人類化抗－ｏｘ４０抗體及其用途 |
| US20160152720A1 (en) | 2014-11-06 | 2016-06-02 | Genentech, Inc. | Combination therapy comprising ox40 binding agonists and tigit inhibitors |
| SG10201807625PA (en) | 2014-11-17 | 2018-10-30 | Genentech Inc | Combination therapy comprising ox40 binding agonists and pd-1 axis binding antagonists |
| KR20250005465A (ko) * | 2015-03-03 | 2025-01-09 | 키맵 리미티드 | 항체, 용도 및 방법 |
| PE20171790A1 (es) | 2015-03-23 | 2017-12-28 | Bayer Pharma AG | Anticuerpos anti-ceacam6 y sus usos |
| DK3303396T5 (da) | 2015-05-29 | 2024-10-07 | Bristol Myers Squibb Co | Antistoffer mod ox40 og anvendelser deraf |
| JP2018521019A (ja) | 2015-06-08 | 2018-08-02 | ジェネンテック， インコーポレイテッド | 抗ｏｘ４０抗体を使用して癌を治療する方法 |
| WO2017063162A1 (zh) * | 2015-10-15 | 2017-04-20 | 苏州丁孚靶点生物技术有限公司 | 抗ox40抗体及其应用 |
| GB201519481D0 (en) * | 2015-11-04 | 2015-12-16 | Cancer Rec Tech Ltd | Immunomodulatory antibodies |
| US10781260B2 (en) * | 2016-08-08 | 2020-09-22 | Sorrento Therapeutics, Inc. | Anti-OX40 binding proteins |
| US11203637B2 (en) | 2016-08-26 | 2021-12-21 | Beigene, Ltd. | Anti-Tim-3 antibodies and use thereof |
| IL272227B2 (en) | 2017-07-27 | 2025-09-01 | iTeos Belgium SA | Anti-tigit antibodies |
| EP3713958A4 (en) | 2017-11-24 | 2021-11-03 | Eucure (Beijing) Biopharma Co., Ltd | ANTI-OX40 ANTIBODIES AND USES THEREOF |
| CN111393529B (zh) | 2018-01-29 | 2022-02-22 | 康源博创生物科技(北京)有限公司 | 与ox40l非竞争结合的抗ox40抗体 |
| TWI831778B (zh) | 2018-05-11 | 2024-02-11 | 澳門商同潤澳門一人有限公司 | 抗ox40的全人抗體及其製備方法和用途 |
| BR112020023746A2 (pt) * | 2018-05-23 | 2021-02-17 | Beigene, Ltd. | anticorpo, composição farmacêutica, método para tratar câncer, ácido nucleico isolado, vetor, célula hospedeira, processo para a produção de um anticorpo e reagente de diagnóstico |
| US20230011916A1 (en) | 2019-11-21 | 2023-01-12 | Beigene, Ltd. | Methods of cancer treatment using anti-ox40 antibodies in combination with pi3 kinase delta inhibitors |
| EP4061421A4 (en) | 2019-11-21 | 2024-05-15 | BeiGene, Ltd. | Treatment of cancer with anti-ox40 antibodies and multi-kinase inhibitors |
| BR112022009147A2 (pt) | 2019-11-21 | 2022-07-26 | Beigene Ltd | Métodos de tratamento do câncer e métodos para aumentar, potencializar ou estimular uma resposta ou função imune |
| US20230002500A1 (en) | 2019-11-21 | 2023-01-05 | Beigene, Ltd. | Methods of cancer treatment using anti-ox40 antibodies in combination with anti-tigit antibodies |
| JP2023503031A (ja) | 2019-11-21 | 2023-01-26 | ベイジーン（ベイジン）カンパニー リミテッド | 化学療法剤との組合せでの抗ｏｘ４０抗体による癌治療の方法 |
| JP2023503399A (ja) | 2019-11-21 | 2023-01-30 | ベイジーン リミテッド | 抗ｔｉｍ３抗体と組み合わせて抗ｏｘ４０抗体を用いるがんを治療する方法 |
-
2019
- 2019-05-22 BR BR112020023746-9A patent/BR112020023746A2/pt active Search and Examination
- 2019-05-22 MX MX2020012567A patent/MX2020012567A/es unknown
- 2019-05-22 AU AU2019272384A patent/AU2019272384A1/en not_active Abandoned
- 2019-05-22 US US17/055,267 patent/US12103974B2/en active Active
- 2019-05-22 CN CN201980034638.8A patent/CN112566935B/zh active Active
- 2019-05-22 EP EP19806419.8A patent/EP3797123A4/en active Pending
- 2019-05-22 SG SG11202011024WA patent/SG11202011024WA/en unknown
- 2019-05-22 JP JP2020565492A patent/JP7489922B2/ja active Active
- 2019-05-22 KR KR1020207035920A patent/KR20210013708A/ko active Pending
- 2019-05-22 WO PCT/CN2019/088013 patent/WO2019223733A1/en not_active Ceased
- 2019-05-22 EA EA202092460A patent/EA202092460A1/ru unknown
- 2019-05-23 TW TW108117808A patent/TW202016133A/zh unknown
-
2020
- 2020-11-06 ZA ZA2020/06931A patent/ZA202006931B/en unknown
- 2020-11-17 IL IL278772A patent/IL278772A/en unknown
- 2020-11-23 MX MX2024013960A patent/MX2024013960A/es unknown
-
2024
- 2024-02-19 JP JP2024022697A patent/JP2024056938A/ja not_active Withdrawn
- 2024-08-28 US US18/818,381 patent/US20240409655A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021524256A5 (https=) | ||
| JP2024056938A5 (https=) | ||
| US9180185B2 (en) | Combination therapy of anti-HER3 antibodies | |
| JP2021527431A5 (https=) | ||
| JP2021524244A5 (https=) | ||
| JP2021510736A5 (https=) | ||
| JP2019529373A5 (ja) | 抗Ｔｉｍ−３抗体 | |
| JP2018534933A5 (https=) | ||
| JP2016538876A5 (https=) | ||
| JP2022533538A5 (https=) | ||
| JP2020522280A5 (https=) | ||
| JP2020515577A5 (https=) | ||
| RU2019139093A (ru) | Фармацевтическая композиция на основе антитела к pd-l1 и ее применение | |
| JP2020522281A5 (https=) | ||
| JP2024540148A5 (https=) | ||
| JP2021525806A5 (https=) | ||
| JP2018533569A5 (https=) | ||
| CN111712521A (zh) | Cd38蛋白抗体及其应用 | |
| JP2021512652A5 (https=) | ||
| CA3029977A1 (en) | Antibodies with low immunogenicity and uses thereof | |
| JP2022517216A5 (https=) | ||
| JP2024522075A5 (https=) | ||
| JP2024519078A5 (https=) | ||
| JP2025502061A5 (https=) | ||
| JP2021528439A5 (https=) |